Issue 110

COMPASS Pathways and the economic outlook for 2023

UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression.

This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval.

With the treatment’s regulation anticipated in 2025, PSYCH sat down with COMPASS Pathways’ CEO, Kabir Nath, to discuss the organisation’s commercialisation strategy and the economic outlook for 2023.

DEA ANNOUNCES PSYCHEDELIC MEDICINE PRODUCTION QUOTAS

In support of psychedelic research, the federal agency now wants 12kg of MDMA produced in 2023.

TRAINING FACILITATORS OF PSILOCYBIN SERVICES IN OREGON

The Psychedelics as Medicine Report revealed psilocybin services in Oregon could generate US$165m a year.

BUSINESS AND INVESTMENT

Numinus reports C$4.2m revenue in Q2 2022.

The anticipated approval of MDMA-assisted therapy in 2024.

Investment trends in psyche delic healthcare.

The process of conducting clinical trials.

Professor David Nutt advocates for psychedelic medicine in Australia.

Field Trip offers laid-off workers free ketamine therapy.

Following the success of the SOLD OUT PSYCH Symposium in 2022, the industry-leading conference returns to the iconic British Museum on Thursday, 6 July 2023.

Super Early Bird tickets now on sale for £249 + VAT.

TICKET REGISTRATION